RSS

alirocumab

The US Food and Drug Administration (FDA) has accepted a supplemental biologics licence application (sBLA) for Praluent (alirocumab) injection as a potential treatment to reduce major adverse cardiovascular events. more

News

Plans have been announced by Sanofi and Regeneron to make Praluent (alirocumab) more accessible and affordable for those patients with the greatest health risk and unmet need. more

News

France's Sanofi and US partner Regeneron Pharmaceuticals have reported that the phase 3 trial of drug Praluent reduced cholesterol in 69% of Japanese patients in a phase 3 trial. more

News